PROCESSES FOR THE PRODUCTION OF FATTY ACID ALKYL ESTERS
    23.
    发明申请
    PROCESSES FOR THE PRODUCTION OF FATTY ACID ALKYL ESTERS 审中-公开
    用于生产脂肪酸亚硝酸酯的方法

    公开(公告)号:WO2008070756A3

    公开(公告)日:2008-10-02

    申请号:PCT/US2007086573

    申请日:2007-12-06

    Inventor: GAO YONG

    Abstract: The present invention provides processes for the formation of fatty acid alkyl esters, which may be used as biodiesel. In particular, the invention provides an esterification process in which a lipid material is contacted with an alcohol in the presence of a metal halide or metal alkoxide conjugated to a solid support. Also provided is a transesterification process in which a lipid material is contacted with an alcohol in the presence of an N-heterocyclic carbene. Also provided is a combination esterification and transesterification process in which a lipid material is contacted with a metal halide or metal alkoxide conjugated to a solid support, and then is contacted with an N-heterocyclic carbene or an alkaline catalyst.

    Abstract translation: 本发明提供了可用作生物柴油的脂肪酸烷基酯的形成方法。 特别地,本发明提供酯化方法,其中脂族物质在与固体支持物缀合的金属卤化物或金属醇盐存在下与醇接触。 还提供了酯交换方法,其中在N-杂环卡宾存在下使脂质物质与醇接触。 还提供了一种组合酯化和酯交换方法,其中脂质材料与金属卤化物或与固体支持物缀合的金属醇盐接触,然后与N-杂环卡宾或碱性催化剂接触。

    PROCESSES FOR THE PRODUCTION OF FATTY ACID ALKYL ESTERS
    24.
    发明申请
    PROCESSES FOR THE PRODUCTION OF FATTY ACID ALKYL ESTERS 审中-公开
    生产脂肪酸烷基酯的方法

    公开(公告)号:WO2008070756A9

    公开(公告)日:2008-08-14

    申请号:PCT/US2007086573

    申请日:2007-12-06

    Inventor: GAO YONG

    Abstract: The present invention provides processes for the formation of fatty acid alkyl esters, which may be used as biodiesel. In particular, the invention provides an esterification process in which a lipid material is contacted with an alcohol in the presence of a metal halide or metal alkoxide conjugated to a solid support. Also provided is a transesterification process in which a lipid material is contacted with an alcohol in the presence of an N-heterocyclic carbene. Also provided is a combination esterification and transesterification process in which a lipid material is contacted with a metal halide or metal alkoxide conjugated to a solid support, and then is contacted with an N-heterocyclic carbene or an alkaline catalyst.

    Abstract translation: 本发明提供了用于形成脂肪酸烷基酯的方法,其可以用作生物柴油。 特别地,本发明提供了一种酯化方法,其中脂质材料在与固体载体结合的金属卤化物或金属醇盐存在下与醇接触。 还提供了一种酯交换方法,其中脂质材料在N-杂环卡宾存在下与醇接触。 还提供了组合酯化和酯交换过程,其中脂质材料与缀合到固体载体上的金属卤化物或金属醇盐接触,然后与N-杂环卡宾或碱性催化剂接触。

    PROCESSES FOR THE PRODUCTION OF FATTY ACID ALKYL ESTERS
    25.
    发明申请
    PROCESSES FOR THE PRODUCTION OF FATTY ACID ALKYL ESTERS 审中-公开
    生产脂肪酸烷基酯的方法

    公开(公告)号:WO2008070756A2

    公开(公告)日:2008-06-12

    申请号:PCT/US2007/086573

    申请日:2007-12-06

    Inventor: GAO, Yong

    Abstract: The present invention provides processes for the formation of fatty acid alkyl esters, which may be used as biodiesel. In particular, the invention provides an esterification process in which a lipid material is contacted with an alcohol in the presence of a metal halide or metal alkoxide conjugated to a solid support. Also provided is a transesterification process in which a lipid material is contacted with an alcohol in the presence of an N-heterocyclic carbene. Also provided is a combination esterification and transesterification process in which a lipid material is contacted with a metal halide or metal alkoxide conjugated to a solid support, and then is contacted with an N-heterocyclic carbene or an alkaline catalyst.

    Abstract translation: 本发明提供了形成脂肪酸烷基酯的方法,其可以用作生物柴油。 特别地,本发明提供了一种酯化方法,其中脂质材料在与固体载体结合的金属卤化物或金属醇盐存在下与醇接触。 还提供了一种酯交换方法,其中脂质材料在N-杂环卡宾存在下与醇接触。 还提供了组合酯化和酯交换过程,其中脂质材料与偶联到固体载体上的金属卤化物或金属醇盐接触,然后与N-杂环卡宾或碱性催化剂接触。

    TREATMENT OF PAIN WITH RESINIFERATOXIN AND RELATED ANALOGS
    26.
    发明申请
    TREATMENT OF PAIN WITH RESINIFERATOXIN AND RELATED ANALOGS 审中-公开
    用残留物和相关模拟物治疗疼痛

    公开(公告)号:WO2008011532A2

    公开(公告)日:2008-01-24

    申请号:PCT/US2007/073913

    申请日:2007-07-19

    CPC classification number: A61K31/353

    Abstract: A method of treating inflammatory pain conditions is provided that involves administering an effective amount of a TRPV1 agonist, such as resiniferatoxin, tinyatoxin and related potent agonists and their analogs, to a patient to selectively induce nerve terminal depolarization block and/or nerve terminal death in select TRPV1-containing neurons, to provide the desired pain relief without significant permanent damage to cell bodies of the select TRPV-1 containing neurons.

    Abstract translation: 提供了一种治疗炎症性疼痛病症的方法,其涉及向患者施用有效量的TRPV1激动剂,例如树脂毒素,微量毒素和相关的有效激动剂及其类似物,以选择性诱导神经末梢去极化阻滞和/或神经末梢死亡 选择含TRPV1的神经元,以提供所需的疼痛缓解,而不会对选择的含TRPV-1的神经元的细胞体造成明显的永久性损伤。

    BIOPOTENTIAL WAVEFORM DATA FUSION ANALYSIS AND CLASSIFICATION METHOD
    28.
    发明申请
    BIOPOTENTIAL WAVEFORM DATA FUSION ANALYSIS AND CLASSIFICATION METHOD 审中-公开
    生物波形数据融合分析和分类方法

    公开(公告)号:WO2006026548A1

    公开(公告)日:2006-03-09

    申请号:PCT/US2005/030662

    申请日:2005-08-30

    Abstract: Biopotential waveforms such as ERPs, EEGs, ECGs, or EMGs are classified accurately by dynamically fusing classification information from multiple electrodes, tests, or other data sources. These different data sources or "channels" are ranked at different time instants according to their respective univariate classification accuracies. Channel rankings are determined during training phase in which classification accuracy of each channel at each time-instant is determined. Classifiers are simple univariate classifiers which only require univariate parameter estimation. Using classification information, a rule is formulated to dynamically select different channels at different time-instants during testing phase. Independent decisions of selected channels at different time instants are fused into a decision fusion vector. Resulting decision fusion vector is optimally classified using a discrete Bayes classifier. Finally, dynamic decision fusion system provides high classification accuracies, is quite flexible in operation, and overcomes major limitations of classifiers applied currently in biopotential waveform studies and clinical applications.

    Abstract translation: 通过动态地融合来自多个电极,测试或其他数据源的分类信息,精确地分类生物电势波形,例如ERPs,EEG,ECG或EMG。 这些不同的数据源或“通道”根据各自的单变量分类精度在不同时刻进行排序。 在训练阶段确定频道排列,其中确定每个时刻的每个频道的分类精度。 分类器是简单的单变量分类器,仅需要单变量参数估计。 使用分类信息,制定了在测试阶段在不同时间点动态选择不同信道的规则。 将不同时刻的选定频道的独立决策融合到决策融合向量中。 所得到的决策融合向量使用离散贝叶斯分类器进行最优分类。 最后,动态决策融合系统提供了高分类精度,操作相当灵活,克服了目前生物电势波形研究和临床应用中应用分类器的主要局限性。

    THERAPEUTIC USE OF METHIONINE FOR THE TREATMENT OR PREVENTION OF MUCOSITIS
    29.
    发明申请
    THERAPEUTIC USE OF METHIONINE FOR THE TREATMENT OR PREVENTION OF MUCOSITIS 审中-公开
    蛋氨酸治疗或预防粘膜炎的治疗用途

    公开(公告)号:WO2005039554A2

    公开(公告)日:2005-05-06

    申请号:PCT/US2004/035626

    申请日:2004-10-27

    CPC classification number: A61K31/198 A61K31/095 A61K41/00 A61K2300/00

    Abstract: Methods of preventing or reducing mucositis in patients who have been exposed to toxic levels of radiation or who are undergoing treatment with platinum-containing anti-tumor compounds are provided. The methods comprise administering an effective amount of a protective agent comprising methionine or a methionine-like moiety to said patient prior to, simultaneously with, or subsequently to exposure to radiation or administration of a platinum-containing anti-tumor compound. Combinations of these time periods can also be employed.

    Abstract translation: 提供了预防或减轻暴露于有毒辐射水平或正在接受含铂抗肿瘤化合物治疗的患者的粘膜炎的方法。 所述方法包括在暴露于辐射或施用含铂抗肿瘤化合物之前,同时或之后向所述患者施用有效量的包含甲硫氨酸或甲硫氨酸样部分的保护剂。 这些时间段的组合也可以使用。

    THERAPEUTIC REGULATION OF DEOXYRIBONUCLEASE-1-LIKE-3 ACTIVITY

    公开(公告)号:WO2003072741A3

    公开(公告)日:2003-09-04

    申请号:PCT/US2003/005654

    申请日:2003-02-26

    Abstract: Deoxyribonuclease 1-like 3 ( D3 ) hydrolyzes lipid-complexed DNA and decreases transfection efficiency in liposomal transfection (lipofection) systems. Accordingly, D1 L3 provides a more accurate test of the efficiency of lipid/liposomal based gene therapy than current standards using deoxyribonuclease 1 (Dl). Moreover, it has been found that mice with systemic lupus erythematosus (lupus) have lowered D1 L3 activity. Therefore, differing therapeutic benefits may result from either the upward or downward therapeutic regulation of D1 L3 activity. For example, blocking D1 L3 activity enhances liposomal transfection for gene therapy, while increasing D 1 L3 activity may enhance destruction of pathogenic DNA, whether viral, bacterial or endogenous. Destruction of pathogenic DNA may provide treatment for lupus, or viral and oncogenic diseases.

Patent Agency Ranking